Cargando…

Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis

OBJECTIVE: Iron deficiency anemia (IDA) has become important with regard to mortality in hemodialysis (HD) patients. Therefore, it is necessary to optimize the treatment of these patients. METHODS: IDA in end-stage renal disease patients on HD was observed in 42 (33.6%) of 125 patients. We examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanai, Toru, Ono, Takashi, Fukumitsu, Toma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643164/
https://www.ncbi.nlm.nih.gov/pubmed/28824065
http://dx.doi.org/10.2169/internalmedicine.8520-16
_version_ 1783271481127469056
author Sanai, Toru
Ono, Takashi
Fukumitsu, Toma
author_facet Sanai, Toru
Ono, Takashi
Fukumitsu, Toma
author_sort Sanai, Toru
collection PubMed
description OBJECTIVE: Iron deficiency anemia (IDA) has become important with regard to mortality in hemodialysis (HD) patients. Therefore, it is necessary to optimize the treatment of these patients. METHODS: IDA in end-stage renal disease patients on HD was observed in 42 (33.6%) of 125 patients. We examined the influence of daily orally iron [sodium ferrous citrate (SFC) iron/tablet 50 mg, 1-2 tablets] on the renal function markers, anemia and iron data for about 6 months. RESULTS: The hematocrit and hemoglobin levels were significantly increased in the patients treated with SFC [hematocrit: before 28.5%±2.1% (mean ± standard deviation), 1st month 30.0%±2.3%, p<0.05; 3rd month 32.4%±2.9%, p<0.05; 6th month 31.3%±3.4%, p<0.05; and hemoglobin: before 9.25±0.70, 1st month 9.72±0.71, p<0.05; 3rd month 10.54±0.96, p<0.05; 6th month 10.25±1.21 g/dL, p<0.05]. The transferrin saturation (TSAT) and serum ferritin levels were significantly increased in the patients treated with SFC (TSAT: before 21.5%±10.0%, 1st-3rd month, 34.1%±15.1%, p<0.05; 6-8th month 34.7%±11.9%, p<0.05; and ferritin: before 38.2±37.1, 6-8th month 67.5±44.0 ng/mL, p<0.05). The present findings clearly indicate that oral iron is an effective route of iron supplementation in HD patients, and no adverse effects associated with SFC occurred during the treatment and follow-up period. CONCLUSION: Our results clearly indicate that oral iron delivered via SFC is a well-tolerated and effective form of iron supplementation in long-term HD and IDA patients in Japan.
format Online
Article
Text
id pubmed-5643164
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-56431642017-10-18 Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis Sanai, Toru Ono, Takashi Fukumitsu, Toma Intern Med Original Article OBJECTIVE: Iron deficiency anemia (IDA) has become important with regard to mortality in hemodialysis (HD) patients. Therefore, it is necessary to optimize the treatment of these patients. METHODS: IDA in end-stage renal disease patients on HD was observed in 42 (33.6%) of 125 patients. We examined the influence of daily orally iron [sodium ferrous citrate (SFC) iron/tablet 50 mg, 1-2 tablets] on the renal function markers, anemia and iron data for about 6 months. RESULTS: The hematocrit and hemoglobin levels were significantly increased in the patients treated with SFC [hematocrit: before 28.5%±2.1% (mean ± standard deviation), 1st month 30.0%±2.3%, p<0.05; 3rd month 32.4%±2.9%, p<0.05; 6th month 31.3%±3.4%, p<0.05; and hemoglobin: before 9.25±0.70, 1st month 9.72±0.71, p<0.05; 3rd month 10.54±0.96, p<0.05; 6th month 10.25±1.21 g/dL, p<0.05]. The transferrin saturation (TSAT) and serum ferritin levels were significantly increased in the patients treated with SFC (TSAT: before 21.5%±10.0%, 1st-3rd month, 34.1%±15.1%, p<0.05; 6-8th month 34.7%±11.9%, p<0.05; and ferritin: before 38.2±37.1, 6-8th month 67.5±44.0 ng/mL, p<0.05). The present findings clearly indicate that oral iron is an effective route of iron supplementation in HD patients, and no adverse effects associated with SFC occurred during the treatment and follow-up period. CONCLUSION: Our results clearly indicate that oral iron delivered via SFC is a well-tolerated and effective form of iron supplementation in long-term HD and IDA patients in Japan. The Japanese Society of Internal Medicine 2017-08-21 2017-09-15 /pmc/articles/PMC5643164/ /pubmed/28824065 http://dx.doi.org/10.2169/internalmedicine.8520-16 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Sanai, Toru
Ono, Takashi
Fukumitsu, Toma
Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis
title Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis
title_full Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis
title_fullStr Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis
title_full_unstemmed Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis
title_short Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis
title_sort beneficial effects of oral iron in japanese patients on hemodialysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643164/
https://www.ncbi.nlm.nih.gov/pubmed/28824065
http://dx.doi.org/10.2169/internalmedicine.8520-16
work_keys_str_mv AT sanaitoru beneficialeffectsoforalironinjapanesepatientsonhemodialysis
AT onotakashi beneficialeffectsoforalironinjapanesepatientsonhemodialysis
AT fukumitsutoma beneficialeffectsoforalironinjapanesepatientsonhemodialysis